Yee-Huang Ku1, Yin-Ching Chuang2, Wen-Liang Yu3,4
1Division of Infectious Disease, Department of Internal Medicine, Chi Mei Medical Center, Liouying; Departments of 2Medical Research and 3Intensive Care Medicine, Chi-Mei Medical Center, Tainan; and 4Department of Medicine, Taipei Medical University, Taipei, Taiwan
Received: April 5, 2007 Revised: May 15, 2007 Accepted: June 25, 2007
Corresponding author: Dr. Wen-Liang Yu, Department of Intensive Care Medicine, Chi-Mei Medical Center, Tainan, Taiwan. E-mail:
This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
Background and Purpose: Strains of extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae have spread widely in Taiwan hospitals. In this study, we evaluated the in vitro antimicrobial activity of tigecycline against ESBL-producing Enterobacteriaceae, including Klebsiella pneumoniae, Serratia marcescens and Enterobacter cloacae.
Methods: 104 confirmed ESBL-producing bacteria were isolated from 4 hospitals in mid- and southern Taiwan between 2000 and 2006. The in vitro activity of tigecycline against these ESBL producers was tested by use of Etest strips.
Results: The minimal tigecycline concentration at which 50% of isolates were inhibited and minimal concentration at which 90% of isolates were inhibited for ESBL-producing isolates ranged from 0.38 to 0.75 μg/mL and 0.5 to 1.5 μg/mL, respectively.
Conclusions: Tigecycline, a new semisynthetic glycylcycline, may be considered an alternative drug of choice for patients infected with ESBL-producing bacteria.
Key words: beta-Lactamase resistance; beta-Lactamases; Enterobacteriaceae; Microbial sensitivity tests; Minocycline
J Microbiol Immunol Infect. 2008;41:332-336.
|
